Brokerages Set Natera, Inc. (NASDAQ:NTRA) Target Price at $225.29

Shares of Natera, Inc. (NASDAQ:NTRA) have been given a consensus recommendation of “Moderate Buy” by the twenty analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and fifteen have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $229.1176.

Several equities analysts recently weighed in on NTRA shares. Evercore ISI increased their price target on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday. Piper Sandler lifted their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Finally, BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a research report on Monday, October 27th.

Insider Buying and Selling

In other news, Director Roelof Botha sold 75,000 shares of Natera stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the transaction, the director owned 1,154,198 shares in the company, valued at $272,529,231.76. This trade represents a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rowan E. Chapman sold 4,366 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $243.10, for a total transaction of $1,061,374.60. Following the sale, the director owned 5,777 shares in the company, valued at $1,404,388.70. The trade was a 43.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 365,164 shares of company stock worth $76,621,909 in the last quarter. 5.63% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hilltop National Bank bought a new position in shares of Natera in the second quarter worth $33,000. Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter worth about $32,000. Oliver Lagore Vanvalin Investment Group bought a new position in Natera in the 2nd quarter worth about $36,000. Sound Income Strategies LLC grew its holdings in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after buying an additional 110 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Stock Down 0.3%

NTRA stock opened at $224.74 on Friday. The business has a 50 day moving average of $211.14 and a 200-day moving average of $178.40. The firm has a market cap of $31.09 billion, a PE ratio of -98.14 and a beta of 1.63. Natera has a 12-month low of $125.38 and a 12-month high of $246.90.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period in the prior year, the firm posted ($0.26) EPS. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, research analysts expect that Natera will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.